Public recall detail

Humalog (insulin lispro) KwikPen 200 Units/mL - Information on Correct Use to Minimize Medication Errors

medium
Recall Safety notice
Quick summary

Quick summary: Humalog (insulin lispro) KwikPen 200 Units/mL - Information on Correct Use to Minimize Medication Errors .

Recommended action

Recommended action: compare your product with the official notice and follow the instructions published by the official source.

Recall details

Quick summary: Humalog (insulin lispro) KwikPen 200 Units/mL - Information on Correct Use to Minimize Medication Errors .

Official details

Affected product details

Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.

Brand

Issue

Health Canada has recently authorized Humalog (insulin lispro) 200 units/mL KwikPen. Humalog (insulin lispro) 200 units/mL solution for injection should ONLY be administered using the Humalog 200 units/mL KwikPen in which it is supplied. Transfer of the higher concentration insulin lispro 200 units/mL from the Humalog 200 units/mL KwikPen to a different insulin delivery system may lead to overdose and severe low blood sugar. When switching between one concentration of Humalog KwikPen and the other, it is important to understand that the same number of units of insulin should be chosen for both devices. The Kwikpen automatically delivers the correct volume of insulin so conversion of dose between devices is not needed. Dose conversions, which are unnecessary given the device design, will lead to under or over dosing, resulting in severe low or high blood sugar.

Additional official information
Background{}
Companies
Audiences

Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.

Official source Monitor products Back to recalls

Starting...

Related recalls

Similar recalls and safety notices.

Loading related recalls...